Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1975 1
1979 1
1980 1
1981 2
1982 2
1983 4
1985 5
1986 3
1987 9
1988 2
1989 2
1990 9
1991 5
1992 9
1993 8
1994 13
1995 10
1996 19
1997 16
1998 17
1999 15
2000 20
2001 20
2002 15
2003 18
2004 14
2005 18
2006 25
2007 22
2008 32
2009 38
2010 47
2011 49
2012 57
2013 61
2014 66
2015 71
2016 68
2017 79
2018 93
2019 84
2020 78
2021 86
2022 79
2023 71
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,229 results

Results by year

Filters applied: . Clear all
Page 1
Autosomal dominant polycystic kidney disease.
Cornec-Le Gall E, Alam A, Perrone RD. Cornec-Le Gall E, et al. Lancet. 2019 Mar 2;393(10174):919-935. doi: 10.1016/S0140-6736(18)32782-X. Epub 2019 Feb 25. Lancet. 2019. PMID: 30819518 Review.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and one of the most common causes of end-stage kidney disease. ...Phase 3 randomised, placebo-controlled clinical trials have clarified aspects of …
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and one of the most c …
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE. Chebib FT, et al. J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18. J Am Soc Nephrol. 2018. PMID: 30228150 Free PMC article. Review.
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. ...Our recommendations are made on the basis of published evidence and our collective experiences during t …
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management o …
Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.
Nowak KL, Hopp K. Nowak KL, et al. Clin J Am Soc Nephrol. 2020 Apr 7;15(4):577-584. doi: 10.2215/CJN.13291019. Epub 2020 Feb 21. Clin J Am Soc Nephrol. 2020. PMID: 32086281 Free PMC article. Review.
Autosomal dominant polycystic kidney disease is characterized by progressive development and enlargement of kidney cysts, leading to ESKD. ...Limited evidence supports that cellular kidney metabolism is also dysregulated in humans with autosomal dominant p …
Autosomal dominant polycystic kidney disease is characterized by progressive development and enlargement of kidney cyst …
Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Torres VE, et al. N Engl J Med. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121377 Free PMC article. Clinical Trial.
BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. ...METHODS: In this phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, we randomly …
BACKGROUND: The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertens …
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment.
Reiterová J, Tesař V. Reiterová J, et al. Int J Mol Sci. 2022 Mar 19;23(6):3317. doi: 10.3390/ijms23063317. Int J Mol Sci. 2022. PMID: 35328738 Free PMC article. Review.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, with an estimated prevalence between 1:1000 and 1:2500. ...The advances in the knowledge of multiple molecular pathways involved in cystogenesis led to the developm …
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease, with an estimated preval …
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International.
Müller RU, Messchendorp AL, Birn H, Capasso G, Cornec-Le Gall E, Devuyst O, van Eerde A, Guirchoun P, Harris T, Hoorn EJ, Knoers NVAM, Korst U, Mekahli D, Le Meur Y, Nijenhuis T, Ong ACM, Sayer JA, Schaefer F, Servais A, Tesar V, Torra R, Walsh SB, Gansevoort RT. Müller RU, et al. Nephrol Dial Transplant. 2022 Apr 25;37(5):825-839. doi: 10.1093/ndt/gfab312. Nephrol Dial Transplant. 2022. PMID: 35134221 Free PMC article. Clinical Trial.
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). ...Since then, considerable practical experience regar …
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the man …
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf SE, Schaefer F. Mekahli D, et al. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022. Clin J Am Soc Nephrol. 2023. PMID: 36719158 Free PMC article. Clinical Trial.
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD). Progression during childhood could be treated before irreversible kidney damage occurs, but trial da …
BACKGROUND: Tolvaptan slows expansion of kidney volume and kidney function decline in adults with autosomal dominant polycystic ki …
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial.
Cukoski S, Lindemann CH, Arjune S, Todorova P, Brecht T, Kühn A, Oehm S, Strubl S, Becker I, Kämmerer U, Torres JA, Meyer F, Schömig T, Hokamp NG, Siedek F, Gottschalk I, Benzing T, Schmidt J, Antczak P, Weimbs T, Grundmann F, Müller RU. Cukoski S, et al. Cell Rep Med. 2023 Nov 21;4(11):101283. doi: 10.1016/j.xcrm.2023.101283. Epub 2023 Nov 7. Cell Rep Med. 2023. PMID: 37935200 Free PMC article. Clinical Trial.
Ketogenic dietary interventions (KDIs) are beneficial in animal models of autosomal-dominant polycystic kidney disease (ADPKD). KETO-ADPKD, an exploratory, randomized, controlled trial, is intended to provide clinical translation of these …
Ketogenic dietary interventions (KDIs) are beneficial in animal models of autosomal-dominant polycystic kidney disease …
Polycystic Kidney Disease.
Ghata J, Cowley BD Jr. Ghata J, et al. Compr Physiol. 2017 Jun 18;7(3):945-975. doi: 10.1002/cphy.c160018. Compr Physiol. 2017. PMID: 28640449 Review.
Common mechanisms associated with renal cyst formation include increased cell proliferation, epithelial fluid secretion, and extracellular matrix remodeling. Hereditary polycystic kidney disease (PKD) is seen as a component of numerous diseases. ...
Common mechanisms associated with renal cyst formation include increased cell proliferation, epithelial fluid secretion, and extracellular m …
Renal embolization.
Grenier N, Petitpierre F, Le Bras Y, Lasserre AS, Cornelis F. Grenier N, et al. Nephrol Ther. 2016 Apr;12 Suppl 1:S139-43. doi: 10.1016/j.nephro.2016.01.009. Epub 2016 Mar 8. Nephrol Ther. 2016. PMID: 26968474
Indications of embolization in nephrology are post-biopsy arteriovenous fistulas, renal graft intolerance, functional exclusion and polycystic kidney disease before transplantation. Others are at the interface between nephrology and urology as angiomyolipomas …
Indications of embolization in nephrology are post-biopsy arteriovenous fistulas, renal graft intolerance, functional exclusion and polyc …
1,229 results